NCI-COG Pediatric MATCH (Molecular Analysis for Therapy Choice) Screening Protocol
This Pediatric MATCH screening and multi-sub-study phase II trial studies how well treatment that is directed by genetic testing works in pediatric patients with solid tumors, non-Hodgkin lymphomas, or histiocytic disorders that have progressed following at least one line of standard systemic therapy and/or for which no standard treatment exists that has been shown to prolong survival.
Genetic tests look at the unique genetic material (genes) of patients' tumor cells. Patients with genetic changes or abnormalities (mutations) may benefit more from treatment which targets their tumor's particular genetic mutation, and may help doctors plan better treatment for patients with solid tumors or non-Hodgkin lymphomas.
Patients undergo biopsy along with tumor mutational screening of the biopsy material for specific, pre-defined mutations, amplifications, or translocations of interest via tumor sequencing and immunohistochemistry. Patients also undergo collection of blood samples for research purposes.
- Brain and Nervous System
- Lymphoma - Non-Hodgkin
- Pediatric (Childhood) Cancer
The study team can discuss eligibility criteria with you as well as any additional questions you may have:
KeywordsEnsartinib, Erdafitinib, Targeted therapy, Genetic testing
Principal InvestigatorWilliam Slayton, M.D.
Sponsoring GroupDepartment of Pediatrics
Begin a new search for other research studies
Studies listed on this site have been approved by a UF Institutional Review Board (IRB), which works to ensure the welfare and rights of research participants as required by federal regulations. Study listings are provided by the UF Clinical and Translational Science Institute in collaboration with UF research teams and the UF IRBs.